Treatment of recalcitrant mycosis fungoides with topical gentian violet

Cowan, Natasha; Coman, Garrett; Duffy, Keith L.; Wada, David A.

doi:10.1016/j.jdcr.2019.03.010

Cited by 6 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 Our laboratory discovered that it is an NADPH oxidase inhibitor and, as such, found that it has antitumor properties in patients with melanoma and lymphoma in vivo. [14][15][16][17] Based on our work, gentian violet was found to have efficacy against early plaque-stated CTCL. In this case report, we demonstrate remission of advanced CTCL using a regimen containing gentian violet, radiation, and mogamulizumab.…”

Section: Discussionmentioning

confidence: 74%

Induction of remission in a patient with end-stage cutaneous T-cell lymphoma by concurrent use of radiation therapy, gentian violet, and mogamulizumab

et al. 2020

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 74%

Induction of remission in a patient with end-stage cutaneous T-cell lymphoma by concurrent use of radiation therapy, gentian violet, and mogamulizumab

et al. 2020

View full text Add to dashboard Cite

“…An interesting in vitro and ex vivo study showed that gentian violet, the widely available inexpensive agent, can act as anticutaneous lymphoma agent through inducing tumour cell apoptosis and blocking its growth [ 28 ]. In addition, there is a case report of a patient with recalcitrant, localized patch disease stage IB that showed improvement and reduction of erythema with gentian violet when applied once daily for 2 months [ 29 ]. Therefore, we included this agent in our guidelines.…”

Section: Resultsmentioning

confidence: 99%

Suggested Guidelines for the Treatment of Mycosis Fungoides in Countries with Limited Resources

Ibrahim

Eltayeb

Ibrahim

et al. 2023

Dermatology Research and Practice

View full text Add to dashboard Cite

The treatment options for mycosis fungoides (MF) have been expanding but unfortunately many of the currently used treatment modalities are unavailable in Egypt and other African/Arab countries. In addition, there is a lack of consensus on the treatment of hypopigmented MF (HMF), which is a frequently encountered variant in our population. We aimed to develop regional treatment guidelines based on the international guidelines but modified to encompass the restricted treatment availability and our institutional experience. Special attention was also given to studies conducted on patients with skin phototype (III-IV). Treatment algorithm was formulated at Ain-Shams cutaneous lymphoma clinic through the collaboration of dermatologists, haematologists, and oncologists. Level of evidence is specified for each treatment option. For HMF, phototherapy is recommended as a first line treatment, while low-dose methotrexate is considered a second line. For early classical MF, we recommend Psoralen-ultraviolet A (PUVA), which is a well-tolerated treatment option in dark phenotype. Addition of either retinoic acid receptor (RAR) agonist and/or methotrexate is recommended as a second line. Total skin electron beam (TSEB) is considered a third-line option. For advanced stage, PUVA plus RAR agonist and/or methotrexate is recommended as first line, TSEB or monochemotherapy is considered a second line option. Polychemotherapy is regarded as a final option. All patients with complete response (CR) enter a maintenance and follow-up schedule. We suggest a practical algorithm for the treatment of MF for patients with dark phenotype living in countries with limited resources.

show abstract

“…In a recently published report, recalcitrant, localized patch disease in a patient with stage IB (T2, N0, M0) cutaneous T cell lymphoma clinically responded to treatment with topical gentian violet (1% solution),. 34 Gentian violet has also been found to be useful in erythema multiforme. Angiopoietin 2 is an angiogenic mediator associated with inflammation and vascular leak.…”

Section: Gentian Violet For Newer Indicationsmentioning

confidence: 99%